Showing results (231-240 of 246) with videos related to
Sort By:
Pageof 25
BJU International|April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groupsMatthew J Roberts, Mark D Chatfield, George Hruby, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2024
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter StudyDavid L Chan, Aimee R Hayes, Ioannis Karfis, et al.Journal for Immunotherapy of Cancer|December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatmentAmrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.Proceedings of the National Academy of Sciences of the United States of America|November 13, 2008
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancerRalph R Weichselbaum, Hemant Ishwaran, Taewon Yoon, et al.Plos One|June 9, 2009
STAT1 pathway mediates amplification of metastatic potential and resistance to therapyNikolai N Khodarev, Paul Roach, Sean P Pitroda, et al.British Journal of Cancer|November 26, 2022
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET scoreDavid L Chan, Aimee R Hayes, Ioannis Karfis, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2019
3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter TrialLouise Emmett, Reuben Tang, Rohan Nandurkar, et al.European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.Plos One|July 5, 2013
SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signatureAmy M Becker, Kathryn H Dao, Bobby Kwanghoon Han, et al.Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.Pageof 25